Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread?

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.154
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2018English

P1.02-05 ALK Positive Lung Cancer: Patient Engagement and Partnership

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Development of Anaplastic Lymphoma Kinase (ALK) Inhibitors and Molecular Diagnosis in ALK Rearrangement-Positive Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2014English

P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

Pulmonary Arterial Hypertension in Congenital Heart Disease

Continuing Cardiology Education
2018English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Other Causes of Pulmonary Arterial Hypertension: Pulmonary Veno-Occlusive Disease, Pulmonary Capillary Hemangiomatosis, Porto-Pulmonary Hypertension, HIV- Associated Pulmonary Arterial Hypertension

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2010English

Non-Tuberculous Mycobacterial Lung Disease (NT MLD ) in Patients With Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension

Pneumonologia i Alergologia Polska
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy